This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
In a single-arm phase Ib/II trial (n=33) of Imprime PGG (a 1,3/1,6 beta-glucan) plus pembrolizumab in previously treated advanced NSCLC, the combination was safe (MTD 4 mg/kg) but did not improve outcomes: confirmed objective response rate 10%, median PFS 2.6 months, median OS 11.1 months. Most patients had progressed on prior anti-PD-1/PD-L1 therapy.
Read the original research
Phase Ib/II study of imprime PGG and pembrolizumab in patients with previously treated advanced non-small cell lung cancer (NSCLC): BTCRC LUN 15-017.
Translational lung cancer research, 2024, 13, 11
Citation
Furqan, Muhammad; Malhotra, Jyoti; Shergill, Ardaman; Liu, Lei; Mott, Sarah L; Pasquinelli, Mary M; Hulbert, Alicia; Kennedy, Kelly; Feldman, Lawrence. (2024). Phase Ib/II study of imprime PGG and pembrolizumab in patients with previously treated advanced non-small cell lung cancer (NSCLC): BTCRC LUN 15-017.. Translational lung cancer research, 2024, 13, 11. https://doi.org/10.21037/tlcr-24-346